BridgeBio Pharma BBIO Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's debt issuance cost amortization?
- BridgeBio Pharma (BBIO) reported debt issuance cost amortization of $1.82M in Q1 2026.
- How has BridgeBio Pharma's debt issuance cost amortization changed year-over-year?
- BridgeBio Pharma's debt issuance cost amortization increased by 12.2% year-over-year, from $1.62M to $1.82M.
- What does debt issuance cost amortization mean?
- The non-cash expense of spreading out the costs of issuing debt.
- How do you interpret debt issuance cost amortization?
- Reflects the ongoing cost of maintaining debt capital; generally stable based on the company's debt structure.
- How does debt issuance cost amortization compare across companies?
- Standard accounting practice for any company with significant long-term debt.